Tiroid Kanserlerinde Hormon Supresyon Tedavileri

Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg, 2014; 140(4): 317–322. doi: 10.1001/jamaoto.2014.1.

Wiltshire JJ, Drake TM, Uttley L, et al. Systematic review of trends in the incidence rates of thyroid cancer. Thyroid, 2016; 26(11): 1541–1552. doi: 10.1089/thy.2016.0100.

Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thy roid nodules and differentiated thyroid cancer. Thyroid, 2016; 26(1): 1–133. doi: 10.1089/thy.2015.0020.

Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf), 2014; 81 Suppl 1: 1–122. doi: 10.1111/cen.12515.

Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid, 2012; 22(11): 1144–1152. doi: 10.1089/thy.2012.0043.

Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low- risk intrathyroid papillary thyroid carcinoma: single- institution results from a large cohort study. J Clin Endocrinol Metab, 2012; 97(12): 4390–4398. doi: 10.1210/jc.2012-1775.

Moon S, Song YS, Kim YA, et al. Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta- analysis. Thyroid, 2017; 27(5): 651–660. doi: 10.1089/thy.2016.0350.

Tala H, Tuttle RM. Contemporary post surgical management of differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):419–429. doi: 10.1016/j.clon.2010.04.005.

National Comprehensive Cancer Network. Thyroid Carcinoma— NCCN Clinical Practice Guidelines in Oncology 2018 [updated 22 May 2018].

Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid,2006;16(12): 1229–1242.doi: 10.1089/thy.2006.16.1229.

Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. doi: 10.1089/thy.2009.0110.

Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014;35(3):433–512. doi: 10.1210/er.2013-1083.

Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341–1349. doi: 10.1089/thy.2010.0178.

Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery. 1995;118(6):1131-1136. doi: 10.1016/s0039-6060(05)80124-2

Kandil E, Krishnan B, Noureldine SI, et al. Hemithyroidectomy: a meta-analysis of postoperative need for hormone replacement and complications. ORL J Otorhinolaryngol Relat Spec. 2013;75(1):6–17. doi: 10.1159/000345498.

Ebina A, Sugitani I, Fujimoto Y, et al. Risk adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients? Surgery. 2014;156(6):1579–1588. doi: 10.1016/j.surg.2014.08.060.

Carayon P, Thomas-Morvan C, Castanas E, et al. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab. 1980;51(4):915–920. doi: 10.1210/jcem-51-4-915.

Francis GL, Waguespack SG, Bauer AJ, et.al. American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 ;25(7):716-759. doi: 10.1089/thy.2014.0460.

Harness JK, Thompson NW, McLeod MK, et.al. Differentiated thyroid carcinoma in children and adolescents. World J Surg. 1992 ;16(4):547-553. doi:10.1007/BF02067317.

Uruno T, Shibuya H, Kitagawa W, et.al.Optimal timing of surgery for differentiated thyroid cancer in pregnant women. World J Surg. 2014;38(3):704–708. doi: 10.1007/s00268-013-2334-9.

McLeod DS, Watters KF, Carpenter AD, et.al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012;97(8):2682–2692. doi: 10.1210/jc.2012-1083.

Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 1991;72(6):1184–1188. doi: 10.1210/jcem-72-6-1184.

Wang LY, Smith AW, Palmer FL, et al. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low-and intermediate risk patients with differentiated thyroid carcinoma. Thyroid. 2015;25(3):300–307 doi: 10.1089/thy.2014.0287.

Camm A, Kirchhof P, Lip G, et al. ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–1420. doi: 10.1093/europace/euq350.

Biondi B, Cooper DS. Benefits of thyrotropin sup pression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010;20(2):135–146. doi: 10.1089/thy.2009.0311.